Us Acromegaly Drugs Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 759.71 Million |
 Market Size (Forecast Year) |
USD 1,247.90 Million |
 CAGR |
% |
| Major Markets Players |
U.S. Acromegaly Drugs Market Segmentation, By Disease Type, (Pseudo acromegaly, Ectopic Acromegaly), Drug Class, (Somatostatin Analogues, Growth Hormone Receptor Antagonists, Dopamine Agonists), Drugs Type (Branded Generic), Route of Administration (Parenteral, Oral), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) - Industry Trends and Forecast to 2031.
U.S. Acromegaly Drugs Market Size
U.S. acromegaly drugs market size was valued at USD 759.71 million in 2023 and is projected to reach USD 1247.90 million by 2031, with a CAGR of 6.4% during the forecast period of 2024 to 2031.
Report Scope and Market Segmentation
|
Attributes |
Acromegaly Drugs Key Market Insights |
|
Segmentation |
By Disease Type: Pseudo acromegaly, Ectopic Acromegaly By Drug Class: Somatostatin Analogues, Growth Hormone Receptor Antagonists, Dopamine Agonists By Drugs Type: Branded Generic By Route of Administration: Parenteral, Oral By End User: Hospitals, Specialty Clinics, Homecare, Others By Distribution Channel: Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy |
|
Countries Covered |
U.S. |
|
Key Market Players |
Novartis AG, Mylan N.V., Ipsen Pharma, Pfizer Inc., Fresenius Kabi USA (A Subsidiary of Fresenius Kabi AG), Zydus Pharmaceuticals Inc. (A Subsidiary of Zydus Cadila), Par Pharmaceuticals (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Chiasma, Inc., Ingenus Pharmaceuticals, LLC, Recordati Rare Diseases (a subsidiary of RECORDATI S.p.A.), Sun Pharmaceutical Industries Ltd. and Sagent Pharmaceuticals, Inc. (A Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.) |
U.S. Acromegaly Drugs Market Dynamics
The U.S. acromegaly drugs market is growing primarily due to increasing focus on the high prevalence of the acromegaly. The availability of wide variety of treatments and presence of several companies focusing on development of acromegaly drugs is also acting as significant growth factors for the market.
Acromegaly drugs market comprises features such as strategic initiatives by market players will impact in launching new product by the manufactures into the market which enhance its demand as well as technological advancements has enhanced the demand of acromegaly drugs. Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative and advanced acromegaly drugs which expected to provide various other opportunities in the acromegaly drugs market. However, the lack of early detection and complication associated with treatment expected to restraint the market growth in the forecast period. The treatment of acromegaly includes multiple types of therapies with advance drug such as somatostatin analogs (SSAs), growth hormone receptor antagonists (GHRAs) and dopamine agonists. However the treatment of acromegaly is very expensive which is hampering the demand of the market. Growing number of dentistry anticipated to escalate the diagnosis of acromegaly disease. Consequently it is estimated that the U.S. acromegaly drugs market will rise up in the coming years.
The acromegaly drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
U.S. Acromegaly Drugs Market Scope
Acromegaly drugs market is segmented on the basis of disease type, drugs class, drugs type, route of administration, end user and distribution channel. The growth among segments helps you to analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Disease Type
- Ectopic Acromegaly
- Pseudo Acromegaly
Drugs Class
- Somatostatin Analogue
- Growth Hormone Receptor Antagonists
- Dopamine Agonists
Drugs Type
- Branded
- Generics
Route of Administration
- Parenteral
- Oral
End User
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy
Acromegaly Drugs Market Share Analysis
U.S. acromegaly drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to U.S. acromegaly drugs market.
Acromegaly Drugs Market Leaders Operating in the Market Are:
- Novartis AG, Mylan N.V.
- Ipsen Pharma
- Pfizer Inc.
- Fresenius Kabi USA (A Subsidiary of Fresenius Kabi AG)
- Zydus Pharmaceuticals Inc. (A Subsidiary of Zydus Cadila)
- Par Pharmaceuticals (A Subsidiary of Endo International plc)
- Hikma Pharmaceuticals PLC
- Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
- Chiasma, Inc.
- Ingenus Pharmaceuticals, LLC
- Recordati Rare Diseases (a subsidiary of RECORDATI S.p.A.)
- Sun Pharmaceutical Industries Ltd.
- Sagent Pharmaceuticals, Inc. (A Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.)
Latest Developments in Acromegaly Drugs Market
- In January 2020, Novartis AG announced the acquisition of the Medicines Company through the consummation of a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation. This acquisition has provided unique opportunity to expand the presence of Novartis AG’s products across the world.
- In November 2019, Novartis AG acquired The Medicines Company to acquire the U.S. based biopharmaceutical company. This acquisition has been estimated to raise the company presence in the U.S. market. Consequently, it will propel the revenue growth of the company.
Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the U.S. acromegaly drugs market which also provides the benefit for organization to improve their offering for acromegaly drugs.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
